AnaptysBio, Inc.
ANAB
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.7B
$56.80
▼ -1.15%
P/E
-52.59
Mkt Cap
$1.7B
52-Wk Range
$11.40–$72.36
52-Week Range
$11.40 - $72.36
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 284.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Novel antibody mechanisms targeting underexploited immune pathways with differentiated clinical profiles
- Strategic partnerships with GSK and Bristol-Myers Squibb providing development expertise and commercialization support
- Experienced management team and scientific advisory board focused on translating immunology research into clinical therapeutics
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Revenue decline expected
Clinical trial progression of lead candidates Imsidolimab and Rosnilimab toward potential regulatory approvals
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+10.6% over 3m
Quality
Excellent
High-growth business (108% revenue growth, 116% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying ANAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 9, 2026
SEP 2, 2026
Reported EPS of -$0.31 vs -$0.41 consensus (+25.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+25.0%
Revenue trend · last 8Q
—
—
+379%
+287%
+103%
+154%
+151%
-8%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$11.0M
$30.0M
$43.1M
$27.8M
$22.3M
$76.3M
$108.2M
$25.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
-206.9%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
—
Latest: Wolfe Research · Aug 31, 2026
vs Industry
How ANAB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related